Katie Matthews

Katie Matthews has a diverse work experience in the field of research and innovation. Katie started their career in 2000 as a PhD student at the University of Edinburgh. After completing their PhD, they worked as a Graduate Research Fellow at UCL and later at King's College Hospital NHS Foundation Trust. In 2009, they joined Weill Cornell Medical College as a Postdoctoral Research Fellow. In 2013, they moved to Innovimmune Biotherapeutics, Inc. where they held the role of Principal Research Scientist, leading a drug discovery program focused on developing new molecular entities for autoimmune diseases. Katie was also involved in securing a $3 million Small Business Innovative Research grant for the development of small molecules targeting pro-inflammatory cytokines. Most recently, Katie worked at DBV Technologies in a Research Management & Innovation role.

Katie Matthews began their education journey in 2000 at The University of Edinburgh, where they pursued a PhD in Immunology with a focus on Veterinary Research, Dendritic cells, and DNA vaccines. Katie completed their doctoral studies in 2004.

After their time at The University of Edinburgh, Katie's educational path is less clear. There is no information regarding specific start or end dates, but they are associated with the Joan & Sanford I. Weill Medical College of Cornell University, where they likely engaged in research related to HIV-1 Vaccine Development.

Additionally, Katie's education may have included studies at King's College London and UCL, as these institutions are mentioned but no specific details about their degree or field of study are provided.

Before their higher education pursuits, Katie attended Westlands High School in Cheshire, UK.